Phosphorylation of amyloid-β peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes

Journal of Biological Chemistry

Volumn 287, Issue 11, 2012, Pages 8641-8651

  Kumar, Sathish ^a   Singh, Sandesh ^a   Hinze, Désirée ^a   Josten, Michaele ^a   Sahl, Hans Georg ^a   Siepmann, Martin ^a   Walter, Jochen ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEINS; ANGIOTENSIN-CONVERTING ENZYME; CLEARANCE RATES; DEGRADING ENZYMES; DUAL ROLE; EXTRACELLULAR; INSULIN-DEGRADING ENZYMES; MICROGLIAL CELLS; NEURODEGENERATION; PROTEIN KINASE A; PROTEOLYTIC ACTIVITIES; PROTEOLYTIC DEGRADATION; SECRETASES;

AMINO ACIDS; CELL MEMBRANES; DEGRADATION; ENZYME ACTIVITY; GLYCOPROTEINS; INSULIN; MASS SPECTROMETRY; PEPTIDES;

PHOSPHORYLATION;

AMYLOID BETA PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; INSULINASE; PLASMIN; PROTEINASE; SERINE;

ALZHEIMER DISEASE; ARTICLE; CLEARANCE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLIC INHIBITION; MICROGLIA; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CELL LINE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FIBRINOLYSIN; HUMANS; INSULYSIN; MICROGLIA; PEPTIDYL-DIPEPTIDASE A; PROTEOLYSIS; SERINE;

EID: 84863236980     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.279133     Document Type: Article

References (75)

1. Masters, C. L., and Beyreuther, K. (2006) Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Aβ amyloid pathway. Brain 129, 2823-2839 (Pubitemid 44684506)
2. Selkoe, D. J. (2001) Alzheimer disease results from the cerebral accumulation and cytotoxicity of amyloid-β protein. J. Alzheimers Dis. 3, 75-80
3. De Strooper, B., Vassar, R., and Golde, T. (2010) The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 6, 99-107
4. Haass, C., and De Strooper, B. (1999) The presenilins in Alzheimer disease: proteolysis holds the key. Science 286, 916-919
5. Tanzi, R. E., St George-Hyslop, P. H., and Gusella, J. F. (1989) Molecular genetic approaches to Alzheimer disease. Trends Neurosci. 12, 152-158 (Pubitemid 19072593)
6. Kamino, K., Sato, S., Sakaki, Y., Yoshiiwa, A., Nishiwaki, Y., Takeda, M., Tanabe, H., Nishimura, T., Ii, K., St George-Hyslop, P. H., Miki, T., and Ogihara, T. (1996) Three different mutations of presenilin-1 gene in early-onset Alzheimer disease families. Neurosci. Lett. 208, 195-198
7. Rossor, M. N., Newman, S., Frackowiak, R. S., Lantos, P., and Kennedy, A. M. (1993) Alzheimer disease families with amyloid precursor protein mutations. Ann. N.Y. Acad. Sci. 695, 198-202 (Pubitemid 23348261)
8. Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., and Bateman, R. J. (2010) Decreased clearance of CNS β-amyloid in Alzheimer disease. Science 330, 1774
9. Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., and Holtzman, D. M. (2006) Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12, 856-861 (Pubitemid 44050079)
10. Cirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M., DeMattos, R. B., and Holtzman, D. M. (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J. Neurosci. 23, 8844-8853 (Pubitemid 37210896)
11. Alvira-Botero, X., and Carro, E. M. (2010) Clearance of amyloid-β peptide across the choroid plexus in Alzheimer disease. Curr. Aging Sci. 3, 219-229
12. Deane, R., Bell, R. D., Sagare, A., and Zlokovic, B. V. (2009) Clearance of amyloid-β peptide across the blood-brain barrier: implication for therapies in Alzheimer disease. CNS Neurol. Disord. Drug Targets 8, 16-30
13. Mandrekar, S., Jiang, Q., Lee, C. Y., Koenigsknecht-Talboo, J., Holtzman, D. M., and Landreth, G. E. (2009) Microglia mediate the clearance of soluble Aβ through fluid-phase macropinocytosis. J. Neurosci. 29, 4252-4262
14. Fiala, M., Lin, J., Ringman, J., Kermani-Arab, V., Tsao, G., Patel, A., Lossinsky, A. S., Graves, M. C., Gustavson, A., Sayre, J., Sofroni, E., Suarez, T., Chiappelli, F., and Bernard, G. (2005) Ineffective phagocytosis of amyloid-β by macrophages of Alzheimer disease patients. J. Alzheimers Dis. 7, 221-232 (Pubitemid 40917251)
15. DeWitt, D. A., Perry, G., Cohen, M., Doller, C., and Silver, J. (1998) Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer disease. Exp. Neurol. 149, 329-340 (Pubitemid 28115071)
16. Panchal, M., Lazar, N., Munoz, N., Fahy, C., Clamagirand, C., Brouard, J. P., Dubost, L., Cohen, P., Brakch, N., and Rholam, M. (2007) Clearance of amyloid-β peptide by neuronal and non-neuronal cells: proteolytic degradation by secreted and membrane-associated proteases. Curr. Neurovasc. Res. 4, 240-251 (Pubitemid 350171824)
17. Yin, K. J., Cirrito, J. R., Yan, P., Hu, X., Xiao, Q., Pan, X., Bateman, R., Song, H., Hsu, F. F., Turk, J., Xu, J., Hsu, C. Y., Mills, J. C., Holtzman, D. M., and Lee, J. M. (2006) Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-β peptide catabolism. J. Neurosci. 26, 10939-10948 (Pubitemid 44772184)
18. Fukami, S., Watanabe, K., Iwata, N., Haraoka, J., Lu, B., Gerard, N. P., Gerard, C., Fraser, P., Westaway, D., St George-Hyslop, P., and Saido, T. C. (2002) Aβ-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Aβ pathology. Neurosci. Res. 43, 39-56 (Pubitemid 34628582)
19. Vekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D., Hartley, D., Chesneau, V., Rosner, M. R., and Selkoe, D. J. (2000) Neurons regulate extracellular levels of amyloid-β protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20, 1657-1665 (Pubitemid 30220363)
20. Qiu, W. Q., and Folstein, M. F. (2006) Insulin, insulin-degrading enzyme, and amyloid-β peptide in Alzheimer disease: review and hypothesis. Neurobiol. Aging 27, 190-198 (Pubitemid 43038542)
21. Iwata, N., and Saido, T. C. (2003) Amyloid-β peptide metabolism and Alzheimer disease. Nippon Yakurigaku Zasshi 122, 5-14 (Pubitemid 36834411)
22. Turner, A. J., Fisk, L., and Nalivaeva, N. N. (2004) Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration. Ann. N.Y. Acad. Sci. 1035, 1-20 (Pubitemid 40362323)
23. Eckman, E. A., and Eckman, C. B. (2005) Aβ-degrading enzymes: modulators of Alzheimer disease pathogenesis and targets for therapeutic intervention. Biochem. Soc. Trans. 33, 1101-1105 (Pubitemid 41659123)
24. Qiu, W. Q., Ye, Z., Kholodenko, D., Seubert, P., and Selkoe, D. J. (1997) Degradation of amyloid-β protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J. Biol. Chem. 272, 6641-6646 (Pubitemid 27118149)
25. Roth, R. A., Mesirow, M. L., Cassell, D. J., Yokono, K., and Baba, S. (1985) Characterization of an insulin-degrading enzyme from cultured human lymphocytes. Diabetes Res. Clin. Pract. 1, 31-39 (Pubitemid 16073181)
26. Zhao, J., Li, L., and Leissring, M. A. (2009) Insulin-degrading enzyme is exported via an unconventional protein secretion pathway. Mol. Neurodegener. 4, 4
27. Bulloj, A., Leal, M. C., Xu, H., Castano, E. M., and Morelli, L. (2009) Insulin-degrading enzyme sorting in exosomes: A secretory pathway for a key brain amyloid-β degrading protease. J. Alzheimers Dis. 19, 79-95
28. Tamboli, I. Y., Barth, E., Christian, L., Siepmann, M., Kumar, S., Singh, S., Tolksdorf, K., Heneka, M. T., Lütjohann, D., Wunderlich, P., and Walter, J. (2010) Statins promote the degradation of extracellular amyloid-β peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion. J. Biol. Chem. 285, 37405-37414
29. Glebov, K., Schütze, S., and Walter, J. (2011) Functional relevance of a novel SlyX motif in nonconventional secretion of insulin-degrading enzyme. J. Biol. Chem. 286, 22711-22715
30. Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., and Guenette, S. (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid-β protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U.S.A. 100, 4162-4167 (Pubitemid 36418174)
31. Farris, W., Mansourian, S., Leissring, M. A., Eckman, E. A., Bertram, L., Eckman, C. B., Tanzi, R. E., and Selkoe, D. J. (2004) Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid-β protein. Am. J. Pathol. 164, 1425-1434 (Pubitemid 38387808)
32. Miller, B. C., Eckman, E. A., Sambamurti, K., Dobbs, N., Chow, K. M., Eckman, C. B., Hersh, L. B., and Thiele, D. L. (2003) Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc. Natl. Acad. Sci. U.S.A. 100, 6221-6226 (Pubitemid 36576957)
33. Leissring, M. A., Farris, W., Chang, A. Y., Walsh, D. M., Wu, X., Sun, X., Frosch, M. P., and Selkoe, D. J. (2003) Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093 (Pubitemid 38032786)
34. Kumar, S., Rezaei-Ghaleh, N., Terwel, D., Thal, D. R., Richard, M., Hoch, M., McDonald, J. M., Wüllner, U., Glebov, K., Heneka, M. T., Walsh, D. M., Zweckstetter, M., and Walter, J. (2011) Extracellular phosphorylation of the amyloid-β peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer disease. EMBO J. 30, 2255-2265
35. Kumar, S., and Walter, J. (2011) Phosphorylation of amyloid-β (Aβ) peptides: a trigger for formation of toxic aggregates in Alzheimer disease. Aging 3, 803-812
36. Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., and Selkoe, D. J. (1998) Insulindegrading enzyme regulates extracellular levels of amyloid-β protein by degradation. J. Biol. Chem. 273, 32730-32738 (Pubitemid 28557658)
37. Haass, C., and Selkoe, D. J. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer amyloid-β peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112 (Pubitemid 46432529)
38. Abramowski, D., Wiederhold, K. H., Furrer, U., Jaton, A. L., Neuenschwander, A., Runser, M. J., Danner, S., Reichwald, J., Ammaturo, D., Staab, D., Stoeckli, M., Rueeger, H., Neumann, U., and Staufenbiel, M. (2008) Dynamics of Aβ turnover and deposition in different β-amyloid precursor protein transgenic mouse models following γ-secretase inhibition. J. Pharmacol. Exp. Ther. 327, 411-424
39. Deane, R., Sagare, A., and Zlokovic, B. V. (2008) The role of the cell-surface LRP and soluble LRP in blood-brain barrier Aβ clearance in Alzheimer disease. Curr. Pharm. Des. 14, 1601-1605 (Pubitemid 352002987)
40. Cole, G. M., Bell, L., Truong, Q. B., and Saitoh, T. (1992) An endosomal-lysosomal pathway for degradation of amyloid precursor protein. Ann. N.Y. Acad. Sci. 674, 103-117 (Pubitemid 23077399)
41. Mooradian, A. D. (1988) Effect of aging on the blood-brain barrier. Neurobiol. Aging 9, 31-39
42. Eikelenboom, P., Veerhuis, R., van Exel, E., Hoozemans, J. J., Rozemuller, A. J., and van Gool, W. A. (2011) The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer disease: neuropathological, epidemiological, and genetic evidence. Curr. Alzheimer Res. 8, 142-150
43. Authier, F., Posner, B. I., and Bergeron, J. J. (1996) Insulin-degrading enzyme. Clin. Invest. Med. 19, 149-160 (Pubitemid 26225900)
44. Bennett, R. G., Duckworth, W. C., and Hamel, F. G. (2000) Degradation of amylin by insulin-degrading enzyme. J. Biol. Chem. 275, 36621-36625 (Pubitemid 32002062)
45. Fawcett, J., Hamel, F. G., Bennett, R. G., Vajo, Z., and Duckworth, W. C. (2001) Insulin and analogue effects on protein degradation in different cell types. Dissociation between binding and activity. J. Biol. Chem. 276, 11552-11558
46. Duckworth, W. C., Bennett, R. G., and Hamel, F. G. (1998) Insulin degradation: progress and potential. Endocr. Rev. 19, 608-624 (Pubitemid 28467714)
47. Kurochkin, I. V. (2001) Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem. Sci. 26, 421-425
48. Shen, Y., Joachimiak, A., Rosner, M. R., and Tang, W. J. (2006) Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature 443, 870-874 (Pubitemid 44622699)
49. Walter, J., Schindzielorz, A., Grünberg, J., and Haass, C. (1999) Phosphorylation of presenilin-2 regulates its cleavage by caspases and retards progression of apoptosis. Proc. Natl. Acad. Sci. U.S.A. 96, 1391-1396 (Pubitemid 29098461)
50. Fluhrer, R., Friedlein, A., Haass, C., and Walter, J. (2004) Phosphorylation of presenilin-1 at the caspase recognition site regulates its proteolytic processing and the progression of apoptosis. J. Biol. Chem. 279, 1585-1593 (Pubitemid 38084422)
51. Johnson, G. V. (2006) Tau phosphorylation and proteolysis: insights and perspectives. J. Alzheimers Dis. 9, 243-250
52. Wang, D. S., Dickson, D. W., and Malter, J. S. (2006) β-Amyloid degradation and Alzheimer disease. J. Biomed. Biotechnol. 2006, 58406
53. Carson, J. A., and Turner, A. J. (2002) Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J. Neurochem. 81, 1-8 (Pubitemid 34808849)
54. Iwata, N., Mizukami, H., Shirotani, K., Takaki, Y., Muramatsu, S., Lu, B., Gerard, N. P., Gerard, C., Ozawa, K., and Saido, T. C. (2004) Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-β peptide in mouse brain. J. Neurosci. 24, 991-998 (Pubitemid 38146610)
55. Liu, Y., Guan, H., Beckett, T. L., Juliano, M. A., Juliano, L., Song, E. S., Chow, K. M., Murphy, M. P., and Hersh, L. B. (2007) In vitro and in vivo degradation of Aβ peptide by peptidases coupled to erythrocytes. Peptides 28, 2348-2355 (Pubitemid 350116309)
56. Howell, S., Nalbantoglu, J., and Crine, P. (1995) Neutral endopeptidase can hydrolyze β-amyloid(1-40) but shows no effect on β-amyloid precursor protein metabolism. Peptides 16, 647-652
57. Betts, V., Leissring, M. A., Dolios, G., Wang, R., Selkoe, D. J., and Walsh, D. M. (2008) Aggregation and catabolism of disease-associated intra-Aβ mutations: reduced proteolysis of Aβ A21G by neprilysin. Neurobiol. Dis. 31, 442-450
58. Iwata, N., Higuchi, M., and Saido, T. C. (2005) Metabolism of amyloid-β peptide and Alzheimer disease. Pharmacol. Ther. 108, 129-148 (Pubitemid 41527082)
59. Barker, R., Love, S., and Kehoe, P. G. (2010) Plasminogen and plasmin in Alzheimer disease. Brain Res. 1355, 7-15
60. Melchor, J. P., and Strickland, S. (2005) Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost. 93, 655-660 (Pubitemid 40485400)
61. Madani, R., Nef, S., and Vassalli, J. D. (2003) Emotions are building up in the field of extracellular proteolysis. Trends Mol. Med. 9, 183-185 (Pubitemid 36713386)
62. Tucker, H. M., Kihiko, M., Caldwell, J. N., Wright, S., Kawarabayashi, T., Price, D., Walker, D., Scheff, S., McGillis, J. P., Rydel, R. E., and Estus, S. (2000) The plasmin system is induced by and degrades amyloid-β aggregates. J. Neurosci. 20, 3937-3946 (Pubitemid 30365663)
63. Tucker, H. M., Kihiko-Ehmann, M., Wright, S., Rydel, R. E., and Estus, S. (2000) Tissue plasminogen activator requires plasminogen to modulate amyloid-β neurotoxicity and deposition. J. Neurochem. 75, 2172-2177
64. Miners, J. S., van Helmond, Z., Raiker, M., Love, S., and Kehoe, P. G. (2010) ACE variants and association with brain Aβ levels in Alzheimer disease. Am. J. Transl. Res. 3, 73-80
65. Kehoe, P. G., Russ, C., McIlory, S., Williams, H., Holmans, P., Holmes, C., Liolitsa, D., Vahidassr, D., Powell, J., McGleenon, B., Liddell, M., Plomin, R., Dynan, K., Williams, N., Neal, J., Cairns, N. J., Wilcock, G., Passmore, P., Lovestone, S., Williams, J., and Owen, M. J. (1999) Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat. Genet. 21, 71-72 (Pubitemid 29036286)
66. Miners, S., Ashby, E., Baig, S., Harrison, R., Tayler, H., Speedy, E., Prince, J. A., Love, S., and Kehoe, P. G. (2009) Angiotensin-converting enzyme levels and activity in Alzheimer disease: differences in brain and cerebrospinal fluid ACE and association with ACE1 genotypes. Am. J. Transl. Res. 1, 163-177
67. Thornton-Wells, T. A., Moore, J. H., Martin, E. R., Pericak-Vance, M. A., and Haines, J. L. (2008) Confronting complexity in late-onset Alzheimer disease: application of two-stage analysis approach addressing heterogeneity and epistasis. Genet. Epidemiol. 32, 187-203 (Pubitemid 351550366)
68. Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J. C., Carrasquillo, M. M., Abraham, R., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Jones, N., Stretton, A., Thomas, C., Richards, A., Ivanov, D., Widdowson, C., Chapman, J., Lovestone, S., Powell, J., Proitsi, P., Lupton, M. K., Brayne, C., Rubinsztein, D. C., Gill, M., Lawlor, B., Lynch, A., Brown, K. S., Passmore, P. A., Craig, D., McGuinness, B., Todd, S., Holmes, C., Mann, D., Smith, A. D., Beaumont, H., Warden, D., Wilcock, G., Love, S., Kehoe, P. G., Hooper, N. M., Vardy, E. R., Hardy, J., Mead, S., Fox, N. C., Rossor, M., Collinge, J., Maier, W., Jessen, F., Rüther, E., Schürmann, B., Heun, R., Kolsch, H., van den, B. H., Heuser, I., Kornhuber, J., Wiltfang, J., Dichgans, M., Frolich, L., Hampel, H., Gallacher, J., Hull, M., Rujescu, D., Giegling, I., Goate, A. M., Kauwe, J. S., Cruchaga, C., Nowotny, P., Morris, J. C., Mayo, K., Sleegers, K., Bettens, K., Engelborghs, S., De Deyn, P. P., Van, B. C., Livingston, G., Bass, N. J., Gurling, H., McQuillin, A., Gwilliam, R., Deloukas, P., Al-Chalabi, A., Shaw, C. E., Tsolaki, M., Singleton, A. B., Guerreiro, R., Muhleisen, T. W., Nothen, M. M., Moebus, S., Jockel, K. H., Klopp, N., Wichmann, H. E., Pankratz, V. S., Sando, S. B., Aasly, J. O., Barcikowska, M., Wszolek, Z. K., Dickson, D. W., Graff-Radford, N. R., Petersen, R. C., van Duijn, C. M., Breteler, M. M., Ikram, M. A., DeStefano, A. L., Fitzpatrick, A. L., Lopez, O., Launer, L. J., Seshadri, S., Berr, C., Campion, D., Epelbaum, J., Dartigues, J. F., Tzourio, C., Alperovitch, A., Lathrop, M., Feulner, T. M., Friedrich, P., Riehle, C., Krawczak, M., Schreiber, S., Mayhaus, M., Nicolhaus, S., Wagenpfeil, S., Steinberg, S., Stefansson, H., Stefansson, K., Snaedal, J., Bjornsson, S., Jonsson, P. V., Chouraki, V., Genier-Boley, B., Hiltunen, M., Soininen, H., Combarros, O., Zelenika, D., Delepine, M., Bullido, M. J., Pasquier, F., Mateo, I., Frank-Garcia, A., Porcellini, E., Hanon, O., Coto, E., Alvarez, V., Bosco, P., Siciliano, G., Mancuso, M., Panza, F., Solfrizzi, V., Nacmias, B., Sorbi, S., Bossu, P., Piccardi, P., Arosio, B., Annoni, G., Seripa, D., Pilotto, A., Scarpini, E., Galimberti, D., Brice, A., Hannequin, D., Licastro, F., Jones, L., Holmans, P. A., Jonsson, T., Riemenschneider, M., Morgan, K., Younkin, S. G., Owen, M. J., O'Donovan, M., Amouyel, P., and Williams, J. (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33, and CD2AP are associated with Alzheimer disease. Nat. Genet. 43, 429-435
69. Seshadri, S., Fitzpatrick, A. L., Ikram, M. A., DeStefano, A. L., Gudnason, V., Boada, M., Bis, J. C., Smith, A. V., Carassquillo, M. M., Lambert, J. C., Harold, D., Schrijvers, E. M., Ramirez-Lorca, R., Debette, S., Longstreth, W. T., Jr., Janssens, A. C., Pankratz, V. S., Dartigues, J. F., Hollingworth, P., Aspelund, T., Hernandez, I., Beiser, A., Kuller, L. H., Koudstaal, P. J., Dickson, D. W., Tzourio, C., Abraham, R., Antunez, C., Du, Y., Rotter, J. I., Aulchenko, Y. S., Harris, T. B., Petersen, R. C., Berr, C., Owen, M. J., Lopez-Arrieta, J., Varadarajan, B. N., Becker, J. T., Rivadeneira, F., Nalls, M. A., Graff-Radford, N. R., Campion, D., Auerbach, S., Rice, K., Hofman, A., Jonsson, P. V., Schmidt, H., Lathrop, M., Mosley, T. H., Au, R., Psaty, B. M., Uitterlinden, A. G., Farrer, L. A., Lumley, T., Ruiz, A., Williams, J., Amouyel, P., Younkin, S. G., Wolf, P. A., Launer, L. J., Lopez, O. L., van Duijn, C. M., and Breteler, M. M. (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303, 1832-1840
70. Naj, A. C., Jun, G., Beecham, G. W., Wang, L. S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., Larson, E. B., Bird, T. D., Boeve, B. F., Graff-Radford, N. R., De Jager, P. L., Evans, D., Schneider, J. A., Carrasquillo, M. M., Ertekin-Taner, N., Younkin, S. G., Cruchaga, C., Kauwe, J. S., Nowotny, P., Kramer, P., Hardy, J., Huentelman, M. J., Myers, A. J., Barmada, M. M., Demirci, F. Y., Baldwin, C. T., Green, R. C., Rogaeva, E., St George-Hyslop, P., Arnold, S. E., Barber, R., Beach, T., Bigio, E. H., Bowen, J. D., Boxer, A., Burke, J. R., Cairns, N. J., Carlson, C. S., Carney, R. M., Carroll, S. L., Chui, H. C., Clark, D. G., Corneveaux, J., Cotman, C. W., Cummings, J. L., DeCarli, C., DeKosky, S. T., az-Arrastia, R., Dick, M., Dickson, D. W., Ellis, W. G., Faber, K. M., Fallon, K. B., Farlow, M. R., Ferris, S., Frosch, M. P., Galasko, D. R., Ganguli, M., Gearing, M., Geschwind, D. H., Ghetti, B., Gilbert, J. R., Gilman, S., Giordani, B., Glass, J. D., Growdon, J. H., Hamilton, R. L., Harrell, L. E., Head, E., Honig, L. S., Hulette, C. M., Hyman, B. T., Jicha, G. A., Jin, L. W., Johnson, N., Karlawish, J., Karydas, A., Kaye, J. A., Kim, R., Koo, E. H., Kowall, N. W., Lah, J. J., Levey, A. I., Lieberman, A. P., Lopez, O. L., Mack, W. J., Marson, D. C., Martiniuk, F., Mash, D. C., Masliah, E., McCormick, W. C., McCurry, S. M., McDavid, A. N., McKee, A. C., Mesulam, M., Miller, B. L., Miller, C. A., Miller, J. W., Parisi, J. E., Perl, D. P., Peskind, E., Petersen, R. C., Poon, W. W., Quinn, J. F., Rajbhandary, R. A., Raskind, M., Reisberg, B., Ringman, J. M., Roberson, E. D., Rosenberg, R. N., Sano, M., Schneider, L. S., Seeley, W., Shelanski, M. L., Slifer, M. A., Smith, C. D., Sonnen, J. A., Spina, S., Stern, R. A., Tanzi, R. E., Trojanowski, J. Q., Troncoso, J. C., Van, D., V, Vinters, H. V., Vonsattel, J. P., Weintraub, S., Welsh-Bohmer, K. A., Williamson, J., Woltjer, R. L., Cantwell, L. B., Dombroski, B. A., Beekly, D., Lunetta, K. L., Martin, E. R., Kamboh, M. I., Saykin, A. J., Reiman, E. M., Bennett, D. A., Morris, J. C., Montine, T. J., Goate, A. M., Blacker, D., Tsuang, D. W., Hakonarson, H., Kukull, W. A., Foroud, T. M., Haines, J. L., Mayeux, R., Pericak-Vance, M. A., Farrer, L. A., and Schellenberg, G. D. (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33, and EPHA1 are associated with late-onset Alzheimer disease. Nat. Genet. 43, 436-441
71. Oba, R., Igarashi, A., Kamata, M., Nagata, K., Takano, S., and Nakagawa, H. (2005) The N-terminal active center of human angiotensin-converting enzyme degrades Alzheimer amyloid-β peptide. Eur. J. Neurosci. 21, 733-740 (Pubitemid 40363508)
72. Hemming, M. L., and Selkoe, D. J. (2005) Amyloid-β protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J. Biol. Chem. 280, 37644-37650 (Pubitemid 41642372)
73. Hu, J., Igarashi, A., Kamata, M., and Nakagawa, H. (2001) Angiotensinconverting enzyme degrades Alzheimer amyloid-β peptide (Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity. J. Biol. Chem. 276, 47863-47868
74. Milton, N. G. (2005) Phosphorylated amyloid-β: the toxic intermediate in Alzheimer disease neurodegeneration. Subcell. Biochem. 38, 381- 402
75. Milton, N. G. (2001) Phosphorylation of amyloid-β at the serine 26 residue by human Cdc2 kinase. Neuroreport 12, 3839-3844